IMCD Indonesia strengthens its life science portfolio with the acquisition of PT Megasetia Agung Kimia
17 November 2021 - 7:00PM
IMCD Indonesia strengthens its life science portfolio with the
acquisition of PT Megasetia Agung Kimia
ROTTERDAM, The Netherlands (17 November 2021) –
IMCD N.V. (“IMCD” or “Company”), a leading distributor of
speciality chemicals and ingredients, today announces that IMCD
Indonesia has signed an agreement to acquire 100% of the shares of
PT Megasetia Agung Kimia (“Megasetia”) in Indonesia. Megasetia is
an excellent fit with IMCD’s life science strategy and provides a
significant platform for further growth in the life science
segments in Indonesia.
The transaction will take place in two tranches,
with IMCD now acquiring 70% of Megasetia’s share capital and the
remaining 30% in 2025. The management of Megasetia will continue to
lead the company post completion of the first tranche.
Founded in 1995, Megasetia is the leading
distributor of speciality ingredients for the pharmaceuticals
industry in Indonesia. In addition, it covers the personal care,
home care, animal health, and industrial markets, offering
end-to-end solutions to its customers and partners with 3
laboratories, 6 offices, and 6 warehouses across Indonesia.
Megasetia generated a revenue of approximately IDR 974 billion (ca.
EUR 60 million) in 2020 with around 160 employees. It currently
serves more than 1,000 customers and represents over 50 of the
world’s leading ingredients producers.
“Indonesia is South East Asia’s largest economy and this
acquisition provides excellent growth opportunities to strengthen
IMCD’s positioning in the life science segments. In addition, it
enables us to enhance our offering to local customers and
partners,” said Haiko Zuidhoff, Vice President of IMCD APAC.
“We are delighted to be part of IMCD’s global network. We are
confident that our life science portfolio will complement their
offering to customers and suppliers,” commented Suryani Hartoyo,
President Director of Megasetia. “Our culture of growth through
market knowledge, technical innovation, and high level of services,
is very well aligned with IMCD’s strategy,” concluded Hartoyo.
The closing of the transaction is expected to take place in
December 2021.
Attached, please find a pdf format of the press
release, the main picture, and its caption.
- Photo - IMCD Indonesia strengthens its life science portfolio
with the acquisition of PT Megasetia Agung Kimia
- Photo Caption - IMCD Indonesia strengthens its life science
portfolio with the acquisition of PT Megasetia Agung Kimia
- Press Release - IMCD Indonesia strengthens its life science
portfolio with the acquisition of PT Megasetia Agung Kimia
IMCD NV (EU:IMCD)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
IMCD NV (EU:IMCD)
Historical Stock Chart
Von Apr 2023 bis Apr 2024